Posted by Michael Wonder on 10 Dec 2020
FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
8 December 2020 - If approved, Nucala would be the only treatment approved in the US for use in four eosinophil-driven diseases.
GlaxoSmithKline today announced that the US FDA has accepted a regulatory submission seeking approval for the use of its anti-IL5 biologic Nucala (mepolizumab) as a treatment for patients with chronic rhinosinusitis with nasal polyps.
